Andrew E. Renison

Associate

+1 202 408 4123 +1 202 408 4123
andrew.renison@finnegan.com andrew.renison@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Andrew's work in

Andrew Renison focuses his practice on U.S. district court litigation, with particular experience related to patent litigation involving the Hatch-Waxman Act governing FDA approval of pharmaceutical products. He also has experience drafting and prosecuting patent applications before the U.S. Patent and Trademark Office (USPTO) and foreign patent offices.

Andrew's litigation experience includes numerous aspects of trial preparation, such as pre-filing investigations, coordinating fact and expert discovery, taking depositions, working with experts, preparing witnesses for depositions, drafting motions and briefs, and managing day-to-day litigation activities.

Andrew's technical experience focused on the production and performance-testing of metal alloys ceramics. He was a recipient of the Metallurgy Trust Fund Scholarship. While earning his undergraduate degree, he worked on the synthesis and characterization of manganese dioxide nanorods at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland.

Experience

Represents Biogen in a Hatch-Waxman litigation involving twenty-six companies seeking FDA approval to market generic versions of Tecfidera^®.

1:17-cv-00829, D. Del., Judge Stark

Counsel for Otsuka in Hatch-Waxman cases involving 24 companies seeking to market generic copies of Abilify^® following expiration of compound patent covering active ingredient in Abilify®. Only one case still pending following confidential resolutions of all other matters.

1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams

Represented Korea-based client SK Innovation (SKI) in a patent infringement suit against plaintiff Celgard LLC. The court granted SKI’s motion to dismiss for lack of personal jurisdiction and denied Celgard’s motion for preliminary injunction. Affirmed on appeal by Federal Circuit.

3:13-cv-00254, W.D.N.C., Judges Cayer, Cogburn
14-1807, Fed. Cir., Judges Newman, Reyna, Wallach

Insights

Articles

Expert Opinions on Reasonable Royalties Must Have a Basis for Comparison to Licenses on Which They Rely and Tie Them to the Facts of the Case

February 27, 2019

LES Insights

Articles

Supreme Court Restricts Where Patent Owners May Sue for Patent Infringement

May 30, 2017

LES Insights

Articles

Court Dismisses Divided Infringement Claim Because Customer's Data Entry Steps Were Not Attributable to the Defendant Software Vendor

November 29, 2016

LES Insights

Articles

A Prior Agreement to Outsource Manufacturing Does Not Invalidate a Patent

August 16, 2016

LES Insights

Articles

Patent Damages May Not Include Value of a Standard and Need Not Be Based on Smallest Salable Unit

March 29, 2016

LES Insights

Articles

Court Refuses to Summarily Dismiss Patent-Infringement Claims Where Questions Exist As to Whether Some or All of a License Agreement Remains in Effect

January 5, 2016

LES Insights

10 more

News

Press Release

62 Finnegan Attorneys Named to 2018 Capital Pro Bono Honor Roll

April 5, 2019

Admissions and Education

Admissions

District of Columbia
Maryland

Education

George Washington University Law School: J.D., 2013

University of British Columbia: B.S., Materials Engineering, 2009

Andrew's Practices

Patent Litigation: Abbreviated New Drug Application (ANDA) Litigation; Patent Trial; Pre-Trial Strategy
Patent Office Examinations: Prosecution

Andrew's Industries

Biotechnology
Chemical
Clean Energy and Renewables
Nanotechnology
Pharmaceutical
Sports, Fitness, and Outdoor Recreation